Skip to main content
. Author manuscript; available in PMC: 2015 Nov 7.
Published in final edited form as: Nature. 2015 Feb 16;521(7550):90–93. doi: 10.1038/nature14139

Figure 2. The IgA-Low phenotype alters susceptibility to DSS in an IgA-dependent manner.

Figure 2

a-c, DSS treatment of IgA-High/IgA-Low mice; (a) percent initial weight, (b) percentage of ulcerated distal colon, (c) representative H&E-stained histologic sections of IgA-High(n=10) and IgA-Low(n=11) mice. d, e, DSS treatment of WT and pIgR−/− mice after VNAM treatment +IgA-High/IgA-Low fecal transplant; (d) percent initial weight, (e) percentage of ulcerated distal colon. Two-way repeated measures ANOVA: (a) column factor P=0.0285; P<0.001, Sidak's multiple comparisons test, final timepoint, IgA-High(n=10) and IgALow(n=11) mice; (d) column factor P<0.0001, n=15(WT+IgA-High), n=18(WT+IgA-Low), n=20(pIgR−/−+IgA-High), n=21(pIgR−/−+IgA-Low); Tukey's multiple comparison test, final timepoint. Unpaired t-test: (b) P=0.0385, IgA-High(n=10), IgA-Low(n=11) mice. One-way ANOVA: (e) F=8.272, P=0.0007, n=3(WT+IgA-High), n=6(WT+IgA-Low), n=8(pIgR−/−+IgA- High), n=10(pIgR−/−+IgA-Low). All values=mean±s.e.m. Different letters indicate significant differences, Tukey's multiple comparison test. Bars=1 mm; boxeg=mlcerated areas.